Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
about
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk of elevated transaminases ...... and afatinib: a meta-analysis.
@en
type
label
Risk of elevated transaminases ...... and afatinib: a meta-analysis.
@en
prefLabel
Risk of elevated transaminases ...... and afatinib: a meta-analysis.
@en
P2860
P1476
Risk of elevated transaminases ...... and afatinib: a meta-analysis
@en
P2093
Hoda Ahmed
P2860
P304
P356
10.1586/17476348.2016.1115723
P577
2015-12-04T00:00:00Z